149353-75-3

Usage

Uses

Used in Pharmaceutical Research and Development:
N-BOC-4-(4-Carboxyphenyl) piperidine is used as a building block for the synthesis of various pharmaceutical compounds and organic molecules. Its unique structure and properties make it an important compound in medicinal chemistry and drug design, contributing to the creation of new chemical entities for drug development.
Used in Organic Synthesis:
In the field of organic synthesis, N-BOC-4-(4-Carboxyphenyl) piperidine is utilized as a key intermediate due to its versatile reactivity and functional group compatibility. This allows for the efficient construction of complex organic molecules and the development of novel synthetic routes.
Used in Medicinal Chemistry:
N-BOC-4-(4-Carboxyphenyl) piperidine plays a significant role in medicinal chemistry, where it is employed for the design and synthesis of bioactive molecules with potential therapeutic applications. Its unique structure enables the exploration of new chemical space and the optimization of drug candidates for improved efficacy and selectivity.

InChI:InChI=1/C17H23NO4/c1-17(2,3)22-16(21)18-10-8-13(9-11-18)12-4-6-14(7-5-12)15(19)20/h4-7,13H,8-11H2,1-3H3,(H,19,20)

Upstream product

• 586-76-5 4-Bromobenzoic acid 
• 301673-14-3 tert-butyl 4-iodopiperidine-1-carboxylate 
• 149353-84-4 4-(4-carboxyphenyl)-piperidine-hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 106-37-6 1.4-dibromobenzene 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 163209-96-9 tert-butyl 4-(4-bromophenyl)-4-hydroxypiperidine-1-carboxylate 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 619-44-3 methyl 4-iodobenzoate 
• 206446-48-2 tert-butyl 4-[4-(ethoxycarbonyl)phenyl]piperidine-1-carboxylate 
• 32245-87-7 1-(4-Phenyl-piperidin-1-yl)-ethanone 
• 771-99-3 4-phenylpiperidine 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 355379-05-4 4-(4-methoxycarbonyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 679806-74-7 4-(4-chlorocarbonyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 617703-03-4 N-(2-t-butoxycarbonylaminophenyl)-4-(1-t-butoxycarbonylpiperidin-4-yl)benzamide 
• 216956-76-2 1-[4-(1-tert-butoxycarbonylpiperidin-4-yl)benzoyl]-4-[(6-chloronaphthalen-2-yl)sulfonyl]piperazine 
• 569667-91-0 tert-butyl 4-(4-(methoxy(methyl)carbamoyl)phenyl)piperidine-1-carboxylate 
• 864359-18-2 tert-butyl 4-(4-(hydroxymethyl)phenyl)piperidine-1-carboxylate 
• 1207539-17-0 tert-butyl 4-(4-(2-amino-3-carbamoylphenylcarbamoyl)phenyl)piperidine-1-carboxylate 
• 196204-01-0 4-(piperidin-4-yl)-benzoic acid 
• 1622204-19-6 6-(2-methoxyethoxy)-N-methyl-5-{[2-({[4-(piperidin-4-yl)phenyl]carbonyl}amino)pyridin-4-yl]oxy}-1H-indole-1-carboxamide 

Relevant academic research and scientific papers

Chimeric compound for targeted degradation of androgen receptor protein, preparation method of chimeric compound and application of chimeric compound in medicine

The invention relates to a chimera compound for targeted degradation of androgen receptor protein, a preparation method of the chimera compound and application of the chimera compound in medicine. Specifically, the invention relates to a chimera (PROTAC) compound for targeted degradation of AR protein of a fused heterocyclic cerebellar protein (cerebellone) E3 ubiquitin ligase ligand as shown in a general formula (IM), a preparation method of the chimera compound, and application of the chimera compound in medicine, and particularly relates to a chimera (PROTAC) compound for targeted degradation of AR protein of a fused heterocyclic cerebellar protein E3 ubiquitin ligase ligand of a fused heterocyclic cerebellar protein E3 ubiquitin ligase ligand.

Preparation method for synthesizing 1-tert-butyloxycarbonyl -4-(4- carboxyphenyl) piperidine (by machine translation)

The preparation method 1 - of synthesizing)-tert-butyloxycarbonyl - 4 4 4 4 4-carboxyphenyl, piperidine comprises the following steps: reacting dibromobenzene or iodobromide as raw material, with N - Boc - 4 - piperidone to obtain the target product 2, with intermediate 3, and preparing intermediate 3 by hydrogenation or hydrogenation to obtain the target product through intermediate 4, preparation intermediate 3 and carrying out hydrogenation reaction with the carbon dioxide to obtain the target product, which is, suitable for industrial production 4, in large, scale 5. by using common reagent, raw material cost, and the reaction is carried out with carbon dioxide. (by machine translation)

Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors

Starting from the phase II clinical FGFR inhibitor lucitanib (2), we conducted a medicinal chemistry approach by opening the central quinoline skeleton coupled with a scaffold hopping process thus leading to a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives. Compound 25a was identified to show selective and equally high potency against FGFR1/2 and VEGFR2 with IC50 values less than 5.0 nM. Significant antiproliferative effects on both FGFR1/2 and VEGFR2 aberrant cancer cells were observed. In the SNU-16 xenograft model, compound 25a showed tumor growth inhibition rates of 25.0% and 81.0% at doses of 10 mg/kg and 50 mg/kg, respectively, with 5% and 10%body weight loss. In view of the synergistic potential of FGFs and VEGFs in tumor angiogenesis observed in preclinical studies, the FGFR/VEGFR2 dual inhibitor 25a may achieve better clinical benefits.

SALT OF MONOCYCLIC PYRIDINE DERIVATIVE AND CRYSTAL THEREOF

The present invention provides salts consisting of an organocarboxylic acid selected from the group consisting of succinic acid and maleic acid and a compound represented by formula (I) and crystals thereat which can be used as bulk materials for pharmaceuticals.

BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER

The present invention is directed to benzamide derivatives, pharmaceutical compositions containing them, and their use as FASN inhibitors, in for example, the treatment of cancer, obesity related disorders, liver related disorders and viral infections. Such compounds are represented by formula (I) as follows: wherein R1, R2, R3, R4, R5, m, n, (II) and (III) are defined herein.

MONOCYCLIC PYRIDINE DERIVATIVE

The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.

Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities

A new series of thiazole-substituted 1,1,1,3,3,3-hexafluoro-2-propanols were prepared and evaluated as malonyl-CoA decarboxylase (MCD) inhibitors. Key analogs caused dose-dependent decreases in food intake and body weight in obese mice. Acute treatment with these compounds also led to a drop in elevated blood glucose in a murine model of type II diabetes.

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Sulfonyl derivatives

Sulfonyl derivatives represented by general formula (I), salts of the same, and solvates of both: and application of them as drugs: [wherein R1is hydrogen, hydroxyl, nitro or the like; R2and R3are each independently hydrogen, halogeno or the like; R4and R5are each dependently hydrogen, halogeno or the like; Q1is an optionally substituted saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group or the like; Q2is a single bond, oxygen or the like; Q3is, e.g., a group represented by formula (a): T1is carbonyl or the like; and X1and X2are each independently methylidyne or nitrogen]. These compounds exhibit potent Fxa inhibiting activities and serve as excellent anticoagulants which speedily exert satisfactory and persistent anti-thrombotic effects through oral administration and little cause adverse effects.

NOVEL SULFONYL DERIVATIVES

Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.